With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice ...

Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.

Like Leqembi, they clear away the plaques in the brains of people with Alzheimer’s. Eli Lilly has requested FDA approval for a similar monoclonal antibody called donanemab.

Leqembi is the first medicine proven to slow Alzheimer’s. AP. Options outside self-pay are limited. Most of the potential patients are on Medicare, and the federal program’s coverage is narrow ...

Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug Leqembi. Now, more than a year and a half later, we checked back in with ...

Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks. The vast majority of Americans with Alzheimer’s get their health coverage through Medicare.

A second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug ...

The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data ...

Alzheimer’s drug Leqembi received full approval from the U.S. Food and Drug Administration. An expert explains why this is a milestone in the treatment of the progressive disease.

If we’re going to have better drugs like Leqembi to treat Alzheimer’s, we need better, more accessible biomarkers to diagnose it, too.